Article Text

Download PDFPDF
Cohort study
NSAIDs increase bleeding risk in patients with atrial fibrillation on antithrombotic therapy
  1. Emer R McGrath
  1. Department of Neurology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA
  1. Correspondence to : Dr Emer McGrath, Department of Neurology, Massachusetts General Hospital, Wang 835, 55 Fruit Street, Boston, MA 02114, USA; emcgrath2{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


The decision to prescribe antithrombotic therapy in patients with atrial fibrillation (AF) requires a careful assessment of the competing risks of ischaemic stroke and major bleeding, most importantly intracerebral haemorrhage. Non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of haemorrhage and are included in the HAS-BLED score which predicts the 1-year risk of major bleeding in patients with AF receiving oral anticoagulant (OAC) therapy.1 NSAID use has also been associated with an increased risk of stroke and myocardial infarction.2 There is limited data available on the …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.